1. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.;Gottlieb;JAMA,2021
2. National Institutes of Health. Therapeutic management of nonhospitalized adults with COVID-19. In: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Updated October 19, 2021. Accessed November 5, 2021. https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/covid19treatmentguidelines-10-27-2021.pdf
3. National Institutes of Health. Updated COVID-19 Treatment Guidelines Panel’s statement on the prioritization of anti-SARS-CoV-2 monoclonal antibodies for the treatment or prevention of SARS-CoV-2 infection when there are logistical or supply constraints. Updated October 7, 2021. Accessed November 5, 2021. https://www.covid19treatmentguidelines.nih.gov/therapies/updated-statement-on-the-prioritization-of-anti-sars-cov-2-mabs/
4. Office of the Assistant Secretary for Preparedness and Response. Update: distribution and administration of COVID-19 therapeutics. Updated September 15, 2021. Accessed November 5, 2021. https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/Update-13Sept21.aspx
5. US Department of Health and Human Services. HHS announces state/territory-coordinated distribution system for monoclonal antibody therapeutics. Updated September 13, 2021. Accessed November 5, 2021. https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/Update-13Sept21.aspx